Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Eckert & Ziegler SE is a German holding company specializing in isotope technology for medical, scientific, and industrial applications. Headquartered in Berlin, it focuses on the processing of radioisotopes and the development, production, and sale of related components and products. The company operates through three main segments: Isotope Products, Medical, and Other. The Isotope Products segment supplies reference standards, sealed radiation sources, and measurement solutions used in industrial radiometry, quality control, and research laboratories. The Medical segment provides radioactive implants and sources used in cancer therapy, including products for prostate brachytherapy and eye applications such as uveal melanoma treatment, as well as solutions for nuclear-medical imaging. The Other segment consolidates internal services like radiation protection, legal, accounting, IT, and human resources, supporting the operating units. Through its portfolio, Eckert & Ziegler SE plays a specialized role in enabling diagnostic imaging, targeted radiotherapy, and industrial measurement processes worldwide.
Margins and capital returns are both well above average: 24.13% operating margin, ROIC at 17.60%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 5.4%, steady but not accelerating. Free cash flow declined 34% despite revenue growth, conversion is weakening.
Free cash flow declined 34% versus the prior year, cash generation momentum has weakened.
Profitability & Returns
Revenue (TTM)
€317M
▲ +5.4% YoY
Net Income (TTM)
€50M
▲ +44.3% YoY
Op. Margin
23.84%
▲ +1.4pp YoY
ROIC
17.60%
▲ +0.8pp YoY
Cash Flow & Balance Sheet
FCF (FY)
€32M
▼ -34.4% YoY
Op. Cash Flow (FY)
€40M
▼ -24.4% YoY
Net Debt
-€84M
Net Cash Position
Cash & Equiv.
€129M
3Y CAGR: +12.0%
3Y CAGR: +65.0%
Continue Research